Yaming Su

Yaming Su

Auto-generated profile, based on publicly available information

Yaming Su

Clinical Pharmacology and Pharmacometrics, Janssen Research & Development, LLC, Raritan, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
NHNahor Haddish‐Berhane
Nahor Haddish‐Berhane
YSYaming Su
Yaming Su
ARAlberto Russu
Alberto Russu
MTMeena Thayu
Meena Thayu
RKRoland E. Knoblauch
Roland E. Knoblauch
HZHonghui Zhou
Honghui Zhou
Amivantamab has demonstrated durable responses with a tolerable safety profile in non‐small cell lung cancer with EGFR exon 20 insertions (Ex20ins) who progressed after prior platinum chemotherapy. Data supporting the amivantamab recommended phase II dose (RP2D) in this patient population are presented. Pharmacokinetic (PK) analysis and population PK (PopPK) modeling were conducted using serum concentration data obtained following amivantamab intravenous administration (140–1,750 mg). Pharmacodynamics (PDs) were evaluated using depletion of soluble EGFR and MET. Exposure‐response (E‐R) analyses were performed using the primary efficacy end point of objective response rate in patients with EGFR Ex20ins. The E‐R relationship for safety was explored for adverse events of clinical interest. Amivantamab exhibited linear PKs at 350–1,750 mg dose levels following administration, with no maximum tolerated dose identified. A two‐compartment PopPK model with linear clearance adequately described the observed PKs. Body weight was a covariate of clearance and volume of distribution in the central compartment. PopPK modeling showed that a weight‐based, 2‐tier (< 80 and ≥ 80 kg) dosing strategy reduces PK variability and provides comparable exposure across 2 weight groups, with 87% of patients achieving exposures above the target threshold. The final confirmed RP2D of amivantamab was 1,050 mg for < 80 kg (1,400 mg for ≥ 80 kg) weekly in cycle 1 (28 days) and every 2 weeks thereafter. No significant exposure‐efficacy or safety correlation was observed. In conclusion, the amivantamab RP2D is supported by PK, PD, safety, and efficacy analyses. E‐R analyses confirmed that the current regimen provides durable efficacy with tolerable safety.

24 September 2024 in Current Pharmacology Reports
Verified
Journal Article
Closed access
PDF file
LZLiping Zhang
Liping Zhang
YSYaming Su
Yaming Su